表 2. The comparison of treatment for MCDA and DCDA groups.
MCDA组与DCDA组治疗情况对比
| Variable | MCDA
group (n=198) |
DCDA
group (n=208) |
P |
| GA: Gestational age; TBA: Total serum bile acid; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; UDCA: Ursodeoxycholic acid; SAM: S-adenosyl methionine; PPC: Polyene phosphatidylcholine capsules. | |||
| Diagnosis of GA/case (%) | 0.307 | ||
| <32 weeks | 87 (43.9) | 81 (38.9) | |
| ≥32 weeks | 111 (56.1) | 127 (61.1) | |
| TBA at diagnosis/case (%) | 0.815 | ||
| <40 µmoL/L | 160 (80.8) | 169 (81.3) | |
| ≥40 µmoL/L, <100 µmoL/L | 33 (16.7) | 39 (18.7) | |
| ≥100 µmoL/L | 5 (2.5) | 0 (0) | |
| Maximum TBA/case (%) | 0.482 | ||
| <40 µmoL/L | 134 (67.7) | 134 (64.4) | |
| ≥40 µmoL/L, <100 µmoL/L | 52 (26.3) | 70 (33.7) | |
| ≥100 µmoL/L | 8 (6.0) | 3 (1.9) | |
| ALT/(U/L) | 212.4±173.8 | 175.9±141.2 | 0.020 |
| AST/(U/L) | 153.4±121.6 | 141.2±9.8 | 0.020 |
| Medication/case (%) | 0.165 | ||
| None | 15 (7.6) | 9 (4.3) | |
| UDCA usage | 183 (92.4) | 199 (95.7) | |
| UDCA plus SAM/PPC | 150 (81.9) | 147 (73.9) | 0.075 |
| UDCA plus SAM, PPC | 127 (69.4) | 128 (64.3) | 0.588 |
Treatment duration/d,
|
22.7±22.9 | 25.8±22.1 | 0.172 |
| Changing TBA/case (%) | 0.496 | ||
| Invalid | 87 (47.5) | 85 (42.7) | |
| Improvement | 63 (34.4) | 79 (39.7) | |
| Recovery | 33 (18.1) | 35 (17.6) | |